描述 |
Hesperidin methylchalcone (Hesperidin methyl chalcone) 抑制氧化应激,细胞因子产生和 NF-κB 活化。Hesperidin methylchalcone 抑制炎症和疼痛。且具有血管保护活性。 |
---|---|
相关类别 |
|
靶点 |
NF-κB
|
SMILES |
COC1=C(C(/C=C/C2=CC(O)=C(OC)C=C2)=O)C(O)=CC(O[C@H](O3)[C@H](O)[C@@H](O)[C@H](O)[C@H]3CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)=C1 |
参考文献 |
|
密度 | 1.6±0.1 g/cm3 |
---|---|
沸点 | 953.0±65.0 °C at 760 mmHg |
熔点 | 120?°C (dec.)(lit.) |
分子式 | C29H36O15 |
分子量 | 624.587 |
闪点 | 309.5±27.8 °C |
精确质量 | 624.205444 |
PSA | 234.29000 |
LogP | 1.86 |
外观性状 | 黄色粉末 |
蒸汽压 | 0.0±0.3 mmHg at 25°C |
折射率 | 1.672 |
储存条件 |
密闭,阴凉,通风干燥处 |
稳定性 |
遵照规格使用和储存 避免氧化剂 |
计算化学 |
1.疏水参数计算参考值(XlogP):-0.3 2.氢键供体数量:8 3.氢键受体数量:15 4.可旋转化学键数量:10 5.互变异构体数量:15 6.拓扑分子极性表面积234 7.重原子数量:44 8.表面电荷:0 9.复杂度:952 10.同位素原子数量:0 11.确定原子立构中心数量:10 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:1 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
更多 |
1. 性状:固体 2. 密度(g/mL,25℃):未确定 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(?C):120 5. 沸点(?C,):未确定 6. 沸点(?C,5.2kPa):未确定 7. 折射率:未确定 8. 闪点(?C):未确定 9. 比旋光度(?):[α]20/D ?71°, c =1 in ethanol 10. 自燃点或引燃温度(?C):未确定 11. 蒸气压(mmHg,78?C):未确定 12. 饱和蒸气压(kPa,60?C):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(oC):未确定 15. 临界压力(KPa):未确定 16. 油水(辛醇/水)分配系数的对数值:未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性(g/l,at 20 ?C:未确定 |
甲基橙皮苷查尔酮毒性英文版
|
个人防护装备 |
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
RTECS号 | FL7085000 |
Assessment of the antineoplastic potential of chalcones in animal models. Curr. Med. Chem. 20(2) , 186-221, (2013)
One part of chemical space that is endowed with interesting biological properties is the area of the chalcones. With this review, we provide a comprehensive overview of the numerous in vivo animal stu…
|
|
Absorption and elimination of (14C) hesperidin methylchalcone in the rat. Eur. J. Drug Metab. Pharmacokinet. 6(3) , 171-7, (1981)
Hesperidin methylchalcone resorption and excretion were studied in rats, using 14C-labelling. The level of radioactivity in the blood showed a peak 1-2 hours after oral administration of the labelled …
|
|
Inhibitory effect of the Ruscus extract and of the flavonoid hesperidine methylchalcone on increased microvascular permeability induced by various agents in the hamster cheek pouch. J. Cardiovasc. Pharmacol. 22(2) , 225-30, (1993)
The Ruscus extract and the flavonoid hesperidine methylchalcone (HMC) are used in treatment of venous insufficiency. In the present study, we used the hamster cheek pouch preparation and investigated …
|
|
2-Propen-1-one, 1-[4-[[6-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-2-hydroxy-6-methoxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)- |
3-Hydroxy-4-[3-(3-hydroxy-4-methoxyphenyl)acryloyl]-5-methoxyphenyl 6-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside |
HESPERIDIN METHYL CHALCONE |
HESPERIDIN METHYL CHALCONE*PRACTICAL GRA DE |
EINECS 246-128-2 |
MFCD00010438 |
Hesperidine Methyl Chalcone |
(e)-osyl]oxy]-2-hydroxy-6-methoxyphenyl]-3-(3-hydroxy-4-methoxyphenyl) |